Marine Tessarech,Gaëlle Friocourt,Florent Marguet,Maryline Lecointre,Morgane Le Mao,Rodrigo Muñoz Díaz,Cyril Mignot,Boris Keren,Bénédicte Héron,Charlotte De Bie,Koen Van Gassen,Didier Loisel,Benoit Delorme,Steffen Syrbe,Annick Klabunde-Cherwon,Rami Abou Jamra,Meret Wegler,Bert Callewaert,Annelies Dheedene,Merzouka Zidannes-Marinnes,Agnès Guichet,Céline Bris,Patrick Van Bogaert,Florence Biquard,Guy Lenaers,Pascale Marcorelles,Claude Ferec,Bruno Gonzalez,Vincent Procaccio,Antonio Vitobello,Dominique Bonneau,Annie Laquerriere,Salim Khiati,Estelle Colin,Merzouka Zidane-Marinnes

Abstract:Purpose Interneuronopathies are a group of neurodevelopmental disorders characterized by deficient migration and differentiation of gamma-aminobutyric acidergic interneurons resulting in a broad clinical spectrum, including autism spectrum disorders, early-onset epileptic encephalopathy, intellectual disability, and schizophrenic disorders. SP9 is a transcription factor belonging to the Krüppel-like factor and specificity protein family, the members of which harbor highly conserved DNA-binding domains. SP9 plays a central role in interneuron development and tangential migration, but it has not yet been implicated in a human neurodevelopmental disorder. Methods Cases with SP9 variants were collected through international data-sharing networks. To address the specific impact of SP9 variants, in silico and in vitro assays were carried out. Results De novo heterozygous variants in SP9 cause a novel form of interneuronopathy. SP9 missense variants affecting the glutamate 378 amino acid result in severe epileptic encephalopathy because of hypomorphic and neomorphic DNA-binding effects, whereas SP9 loss-of-function variants result in a milder phenotype with epilepsy, developmental delay, and autism spectrum disorder. Conclusion De novo heterozygous SP9 variants are responsible for a neurodevelopmental disease. Interestingly, variants located in conserved DNA-binding domains of KLF/SP family transcription factors may lead to neomorphic DNA-binding functions resulting in a combination of loss- and gain-of-function effects.

De novo variants in SP9 cause a novel form of interneuronopathy characterized by intellectual disability, autism spectrum disorder, and epilepsy with variable expressivity